Subspecialty Ambulatory Quality Cardiology Program

Subspecialty Ambulatory Quality Cardiology Program: An Audit and Feedback Performance Improvement Strategy

Investigators will evaluate the effectiveness of an audit and feedback performance improvement strategy in which cardiology providers receive quarterly emails on ambulatory quality improvement goals.

Study Overview

• Status: Enrolling by invitation
• Conditions: Atrial Fibrillation; Heart Failure With Reduced Ejection Fraction

• Study Type: Observational
• Enrollment (Estimated): 7000

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • NYU Langone Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients seen by a cardiology provider in the ambulatory setting.

Description

Inclusion Criteria for atrial fibrillation quality metric:

• Active diagnosis of atrial fibrillation
• CHADS2VASC of at least 2 in males and at least 3 in females
• Outpatient cardiology visit in past 3 months

Inclusion Criteria for HFrEF quality metric:

• Most recent EF ≤40
• Age 18-90
• Outpatient cardiology visit in past 3 months

Exclusion Criteria for atrial fibrillation quality metric:

• LAAO device
• Hemorrhagic Stroke

Exclusion Criteria for HFrEF quality metric:

• SBP<90
• eGFR<30
• Potassium>5
• Active allergy to MRA
• Acknowledge reason on heart failure alert
• Mechanical circulatory device
• Cardiac amyloid diagnosis

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Quarterly Emails; Quarterly emails on performance will be sent.
Control; Usual Care (no emails on performance).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of patients eligible for medications who are prescribed these medications	Day 1

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of patients with HFrEF prescribed aldosterone antagonists	Day 1
Percentage of patients with Afib prescribed oral anticoagulants	Day 1

Collaborators and Investigators

• Sponsor: NYU Langone Health
• Investigators: Principal Investigator: Amrita Mukhopadhyay, MD, NYU Langone Health

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2024
• Primary Completion (Estimated): April 1, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: December 4, 2025
• First Submitted That Met QC Criteria: December 4, 2025
• First Posted (Actual): December 16, 2025

Study Record Updates

• Last Update Posted (Actual): December 16, 2025
• Last Update Submitted That Met QC Criteria: December 4, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Pathological Conditions, Signs and Symptoms; Atrial Fibrillation
• Other Study ID Numbers: QI-Specialty Ambulatory

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This is a quality improvement (QI) project and individual participant data (IPD) will not be shared with other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No